Business segment information (Tables)

3 Months Ended

Mar. 31, 2015

Schedule of Net Sales by SBU Reporting Segment

The table below presents net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in our Biologics segment.

	Net Sales by SBU
	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2015		2014		Reported Increase (Decrease)			Constant Currency Increase (Decrease)

BioStim	$	37,700	$	37,137		2	%		2	%
Biologics		13,961		13,010		7	%		7	%
Extremity Fixation		21,815		27,066		(19	)%		(9	)%
Spine Fixation		16,286		22,801		(29	)%		(28	)%
Total Net Sales	$	89,762	$	100,014		(10	)%		(7	)%

Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses from continuing operations by SBU reporting segment:

Net margin by SBU	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2015			2014

Net margin:
BioStim	$	14,013		$	15,020
Biologics		5,944			6,502
Extremity Fixation		7,016			6,933
Spine Fixation		(529	)		4,059
Corporate		(306	)		(444	)
Total net margin		26,138			32,070
General and administrative		21,164			17,276
Research and development		5,845			5,933
Amortization of intangible assets		405			584
Costs related to the accounting review and restatements		5,916			8,306
Operating loss	$	(7,192	)	$	(29	)